title: Long-term treatment of patients with HIV-1: the role of atazanavir.
abstract: BACKGROUND
  The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.
  
  
  OBJECTIVE
  To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.
  
  
  METHODS
  Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.
  
  
  RESULTS
  ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.
authors.affiliation: Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Artacho
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: José Vicente
authors.initials: JV
authors.lastname: Fernández-Montero
references.citation: AIDS. 2003 Dec 5;17(18):2603-14
references.pmid: 14685054
references.citation: Curr Med Res Opin. 2005 Oct;21(10):1683-92
references.pmid: 16238909
references.citation: J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9
references.pmid: 15247553
references.citation: Clin Infect Dis. 2007 Oct 15;45(8):e105-8
references.pmid: 17879904
references.citation: AIDS. 2008 Nov 30;22(18):2535-7
references.pmid: 19005277
references.citation: J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7
references.pmid: 17971713
references.citation: J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32
references.pmid: 20032785
references.citation: Infection. 2009 Jun;37(3):233-43
references.pmid: 19169632
references.citation: N Engl J Med. 2006 Nov 16;355(20):2158-9
references.pmid: 17108352
references.citation: J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):174-80
references.pmid: 15905733
references.citation: Lancet. 2008 Aug 23;372(9639):646-55
references.pmid: 18722869
references.citation: Clin Pharmacokinet. 2004;43(15):1071-87
references.pmid: 15568888
references.citation: J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):18-29
references.pmid: 12514410
references.citation: Drug Metab Dispos. 2005 Jun;33(6):764-70
references.pmid: 15764714
references.citation: J Infect Dis. 2007 Apr 1;195(7):973-9
references.pmid: 17330787
references.citation: AIDS. 2006 Jan 2;20(1):35-40
references.pmid: 16327317
references.citation: Expert Opin Pharmacother. 2009 Jul;10(10):1615-29
references.pmid: 19527188
references.citation: HIV Med. 2006 Jul;7(5):317-22
references.pmid: 16945077
references.citation: Ther Clin Risk Manag. 2009 Feb;5(1):99-116
references.pmid: 19436623
references.citation: AIDS. 2007 Jul 31;21(12):1648-51
references.pmid: 17630564
references.citation: AIDS. 2003 Jun 13;17(9):1339-49
references.pmid: 12799555
references.citation: Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8
references.pmid: 16940065
references.citation: Clin Pharmacokinet. 2008;47(3):153-72
references.pmid: 18307370
references.citation: Clin Infect Dis. 2008 Aug 1;47(3):e36-8
references.pmid: 18558878
references.citation: J Antimicrob Chemother. 2008 Jan;61(1):200-5
references.pmid: 17999977
references.citation: JAMA. 2006 Aug 16;296(7):806-14
references.pmid: 16905786
references.citation: AIDS. 2007 Jun 19;21(10):1309-15
references.pmid: 17545707
references.citation: AIDS. 2005 Apr 29;19(7):685-94
references.pmid: 15821394
references.citation: Clin Infect Dis. 2007 Jun 1;44(11):1484-92
references.pmid: 17479947
references.citation: J Infect Dis. 2001 Apr 1;183(7):1126-9
references.pmid: 11237841
references.citation: Antivir Ther. 2006;11(4):421-9
references.pmid: 16856615
references.citation: AIDS. 2006 Mar 21;20(5):711-8
references.pmid: 16514301
references.citation: Antimicrob Agents Chemother. 2003 Apr;47(4):1324-33
references.pmid: 12654666